Substantial Role In Autism Played By Chromosomal Abnormalities
Main Category: AutismAlso Included In: Genetics
Article Date: 18 Jan 2008 - 5:00 PDT
| Patient / Public: | ![]() |
4.27 (11 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
| Article Opinions: | 1 posts |
Genome-wide scans of families affected by autism spectrum disorder (ASD) have revealed new evidence that previously unknown chromosomal abnormalities have a substantial role in the prevalent developmental disorder, according to a report published online Jan. 17th in the American Journal of Human Genetics, a publication of Cell Press. Structural variants in the chromosomes were found to influence ASD with sufficiently high frequency to suggest that genomic analyses be considered in routine clinical workup, according to the researchers.
"Historical studies in identical twins and their families have provided strong evidence for a genetic basis of autism," said Stephen Scherer of The Hospital for Sick Children and the University of Toronto. "Last year, with the Autism Genome Project Consortium, we did an initial study to look at the rate of chromosomal changes in autism. Now, we've really pinned down those numbers."
Autism is a complex developmental disorder found in about one in every 165 children, making it one of the most common forms of developmental disability of childhood. Individuals with ASD have deficits in social interaction and communication and show a preference for repetitive, stereotyped activities. Structural changes, including gains and losses of genes as well as chromosomal translocations (in which a chromosomal segment ends up in the wrong place) or inversions (in which a portion of the genome is oriented backwards) have been previously identified in some individuals with ASD, but their causal role hasn't been clear.
In the new study, the researchers examined structural abnormalities in 427 unrelated ASD cases using both microarray analysis and karyotyping. Microarrays can detect "unbalanced" genetic changes that alter the number of copies of a particular gene. Karyotyping, in which chromosomes are viewed under the microscope, can identify "balanced" translocations or inversions that might otherwise be missed by microarrays.
While most chromosomal abnormalities were inherited, the researchers found that seven percent of children with autism carry structural changes in the genome that are not found in their parents. The rate of such de novo changes in the general population is typically less than one percent, Scherer said.
The researchers detected 13 regions of the genome with overlapping or recurrent chromosomal changes in unrelated people with autism, suggesting that genes located at these sites may cause or add to the complexity of the condition. The most prevalent change, occurring in one percent of ASD cases, was found on chromosome 16, they reported. The altered portion of chromosome 16 has structural characteristics that make it more prone to errors, Scherer noted.
In a subset of ASD cases, the researchers found abnormalities in several genes known to be involved in neuron function. They also identified at least two sites that have previously been linked to mental retardation.
In light of the new findings, Scherer's team also calls for new testing in the clinic.
"From our current data it is already apparent that for a proportion of individuals, it will be possible to describe their ASD based on the underlying structural characteristics of their genome," they wrote.
"If we found certain changes, we could then watch those children closer," Scherer added, noting the critical importance of early diagnosis for autism.
###
The researchers include Christian R. Marshall, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Abdul Noor, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; John B. Vincent, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Anath C. Lionel, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Lars Feuk, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Jennifer Skaug, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Mary Shago, Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada; Rainald Moessner, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Dalila Pinto, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Yan Ren, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Bhooma Thiruvahindrapduram, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Andreas Fiebig, Institute for Clinical Molecular Biology, Christian-Albrechts-University, Keil, Germany; Stefan Schreiber, Institute for Clinical Molecular Biology, Christian-Albrechts-University, Keil, Germany; Jan Friedman, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada; Cees E.J. Ketelaars, Department of Child Psychiatry, University Medical Center Groningen, Groningen, The Netherlands; Yvonne J. Vos, Department of Child Psychiatry, University Medical Center Groningen, Groningen, The Netherlands; Can Ficicioglu, Division of Metabolism, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Susan Kirkpatrick, Department of Medical Genetics, University ofWisconsin, Madison, WI, USA; Rob Nicolson, Department of Psychiatry, University of Western Ontario, London, Ontario, Canada; Leon Sloman, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Anne Summers, Department of Genetics, North York General Hospital, Toronto, Ontario, Canada; Clare A. Gibbons, Department of Genetics, North York General Hospital, Toronto, Ontario, Canada; Ahmad Teebi, Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada; David Chitayat, Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada; Rosanna Weksberg, Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada; Anne Thompson, Offord Centre for Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada; Cathy Vardy, Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Vicki Crosbie, Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Sandra Luscombe, Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Rebecca Baatjes, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada; Lonnie Zwaigenbaum, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada; Wendy Roberts, Autism Research Unit, The Hospital for Sick Children, Toronto, Ontario, Canada, Bloorview Kids Rehab, University of Toronto, Toronto, Ontario, Canada; Bridget Fernandez, Disciplines of Genetics and Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Peter Szatmari, Offord Centre for Child Studies, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada; and Stephen W. Scherer, The Centre for Applied Genomics and Program in Genetics and Genomic Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada.
Source: Cathleen Genova
Cell Press
Visit our autism section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/94469.php>
APA
http://www.medicalnewstoday.com/releases/94469.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Chromosome Damage
posted by RAJ on 25 Jan 2008 at 12:57 pmA spate of studies have been published this year implicating chromosome defects in autism. There are several problems with the methodology that these studies have in common. Genetic mental retardation syndromes have been associated with autism for decades (Fragile X, Tuberous Sclerosis, Angleman Syndrome and others). All of these syndromes have common features, primarily mental retardation, unusual physical features and early onset seizures).
In all these conditions only a minority have enough 'autistic-type' behaviors to qualify for a PDD diagnosis. In the past many of these children would have a primary diagnosis of mental retardation with autistic-type features. The recent studies only look at the subgroup with autistic features, but do not see the majority of cases who present with a diagnosis of mental retardation but do not have enough autistic-type features to qualify for a PDD diagnosis.
Recruiting such a highly selected group can lead to false assumptions and misleading conclusions. For example, there was recent reports associating the family of neurexin genes with autism. The genetic defects reported had all previously been reported in mental retardation, schizophrenia and early focal seizures. A recent study attempted to find if the genetic defects were 'autism' genes or mental retardation genes. The researchers recruited only high functioning autistit subjects (IQ > 70) and found no evidence that this specific genetic defect was associated with high-funtioning autism.
It is important to control for the confounding variable of mental retardation in autistic samples by selecting large samples of high functioning autistic people as a control group.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





